What's in Lupin's pipeline?

Lupin has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Lupin's portfolio?

Top competitors by shared drug class: , Boehringer Ingelheim, Glaxo Grp Ltd, Merck & Co., Novartis.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/lupin.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Lupin — Portfolio Competitive Intelligence Brief

Lupin (LUPIN.NS) pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

LUPIN.NS (NSE) 1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Brovana	ARFORMOTEROL	marketed	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	Cardiovascular	2006-01-01

Therapeutic area mix

Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
Boehringer Ingelheim · 1 shared drug class
Glaxo Grp Ltd · 1 shared drug class
Merck & Co. · 1 shared drug class
Novartis · 1 shared drug class
Oak Pharms Inc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Lupin:

Cite this brief

Drug Landscape (2026). Lupin — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lupin. Accessed 2026-05-14.